125 related articles for article (PubMed ID: 15830012)
1. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
Mejstríková E; Kalina T; Trka J; Starý J; Hrusák O
Leukemia; 2005 Jun; 19(6):1092-4. PubMed ID: 15830012
[No Abstract] [Full Text] [Related]
2. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia.
Piccaluga PP; Arpinati M; Candoni A; Laterza C; Paolini S; Gazzola A; Sabattini E; Visani G; Pileri SA
Leuk Lymphoma; 2011 Feb; 52(2):325-7. PubMed ID: 21077738
[No Abstract] [Full Text] [Related]
3. [Monoclonal antibody therapy targeting surface antigens of leukemic cells].
Meng FY; Fu YB
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):441-3. PubMed ID: 15854546
[No Abstract] [Full Text] [Related]
4. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
[TBL] [Abstract][Full Text] [Related]
5. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg.
Cheung KC; Wong LG; Yeung YM
Leuk Lymphoma; 2008 Mar; 49(3):596-7. PubMed ID: 18297542
[No Abstract] [Full Text] [Related]
6. Value of monoclonal anti-myeloperoxidase (MPO7) for diagnosing acute leukaemia.
Storr J; Dolan G; Coustan-Smith E; Barnett D; Reilly JT
J Clin Pathol; 1990 Oct; 43(10):847-9. PubMed ID: 1977771
[TBL] [Abstract][Full Text] [Related]
7. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Aug; 42(4):675-82. PubMed ID: 11697497
[TBL] [Abstract][Full Text] [Related]
8. CD33+ B-cell precursor acute lymphoblastic leukemia in children: a distinct subgroup of B-cell precursor acute lymphoblastic leukemia.
Hara J; Hosoi G; Okamura T; Osugi Y; Ishihara S; Yumura-Yagi K; Kawa-Ha K; Tawa A
Int J Hematol; 1995 Feb; 61(2):77-84. PubMed ID: 7734715
[TBL] [Abstract][Full Text] [Related]
9. [The use of monoclonal antibodies for immunologic typing and prognosis prediction in acute non-lymphoblastic leukemia].
Chen GB; Tang MH; Yang TY
Zhonghua Nei Ke Za Zhi; 1993 Jun; 32(6):405-8. PubMed ID: 7903627
[TBL] [Abstract][Full Text] [Related]
10. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia.
Cotter M; Rooney S; O'Marcaigh A; Smith OP
Br J Haematol; 2003 Aug; 122(4):687-8. PubMed ID: 12899727
[No Abstract] [Full Text] [Related]
11. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
[TBL] [Abstract][Full Text] [Related]
12. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.
Zwaan CM; Reinhardt D; Jürgens H; Huismans DR; Hählen K; Smith OP; Biondi A; van Wering ER; Feingold J; Kaspers GJ
Leukemia; 2003 Feb; 17(2):468-70. PubMed ID: 12592351
[No Abstract] [Full Text] [Related]
13. Immunotherapy for acute leukemias.
Caron PC; Scheinberg DA
Curr Opin Oncol; 1994 Jan; 6(1):14-22. PubMed ID: 8204688
[TBL] [Abstract][Full Text] [Related]
14. Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells.
Pérez-Oliva AB; Martínez-Esparza M; Vicente-Fernández JJ; Corral-San Miguel R; García-Peñarrubia P; Hernández-Caselles T
Glycobiology; 2011 Jun; 21(6):757-70. PubMed ID: 21278227
[TBL] [Abstract][Full Text] [Related]
15. Variable detection of myeloid antigens in childhood acute lymphoblastic leukaemia.
Howard MR; Thomas L; Reid MM
J Clin Pathol; 1994 Nov; 47(11):1006-9. PubMed ID: 7829673
[TBL] [Abstract][Full Text] [Related]
16. [Monoclonal antibody therapies for acute leukemia].
Takeshita A; Ono R
Rinsho Ketsueki; 2002 May; 43(5):353-6. PubMed ID: 12096485
[No Abstract] [Full Text] [Related]
17. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones.
Firat H; Favier R; Adam M; Leverger G; Landman-Parker J; Cayre Y; Douay L
Leuk Lymphoma; 2001 Jun; 42(1-2):75-82. PubMed ID: 11699224
[TBL] [Abstract][Full Text] [Related]
18. Specific induction of CD33 expression by E2A-HLF: the first evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor.
Akahane K; Inukai T; Inaba T; Kurosawa H; Look AT; Kiyokawa N; Fujimoto J; Goto H; Endo M; Zhang X; Hirose K; Kuroda I; Honna H; Kagami K; Goi K; Nakazawa S; Sugita K
Leukemia; 2010 Apr; 24(4):865-9. PubMed ID: 20147975
[No Abstract] [Full Text] [Related]
19. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
Caron PC; Scheinberg DA
Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221
[TBL] [Abstract][Full Text] [Related]
20. [Antibody therapy for acute leukemia].
Takeshita A
Nihon Rinsho; 2007 Jan; 65 Suppl 1():408-15. PubMed ID: 17474439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
